Neko Health, the Swedish preventive healthcare startup co-founded by Spotify’s Daniel Ek and Hjalmar Nilsonne, has officially launched in the United States, opening its first American outpost in New York City.
The company, which has raised nearly $1 billion in total funding, aims to make comprehensive health screening more proactive and data-driven. According to the company, interest in its preventive technology has surged, with a global waitlist that now exceeds 300,000 individuals.
Preventive Screening and Advanced Diagnostics
Neko Health provides a comprehensive, one-hour assessment designed to screen for underlying conditions involving the blood, skin, and metabolism. To achieve this, the system combines advanced computer vision, artificial intelligence, and broad biomarker diagnostics.
Preface Ventures investor Farooq Abbasi, an early backer of Neko Health who has completed the scan twice, noted substantial improvements in the platform’s diagnostic breadth. Abbasi indicated that while his first-generation scan evaluated 15 blood biomarkers, the latest version has expanded to test 55 distinct biomarkers.
Advocates position the technology as a practical deployment of computer vision in medicine, generating actionable health insights rather than functioning as a superficial wellness product.
The US Healthcare Market and Pricing Dynamics
The company’s expansion into the United States brings it into a healthcare market characterized by notoriously low adoption of preventive care, largely due to cost structures and systemic inefficiencies.
Currently, Neko Health charges $500 for its one-hour diagnostic session. The procedure is not covered by traditional medical insurance, though it is expected to qualify as an eligible expense for consumers using Health Savings Accounts (HSAs). Abbasi argued that preventive healthcare must ultimately become both inexpensive and widely accessible to alter consumer behavior and improve national outcomes.
Scaling Hurdles and Future Expansion
While Neko Health is eyeing a broader expansion across the American market, significant hurdles remain. The company still faces standard startup challenges around operational scaling, clinic footprint expansion, and navigating complex US regulatory environments.
Despite these barriers, early investors express optimism regarding the platform’s ability to demonstrate the value of technology-enabled preventive care and capture demand in a fragmented healthcare ecosystem.
About The Author
